Īrija - angļu - HPRA (Health Products Regulatory Authority)

ethypharm - morphine sulfate - tablet prolonged release - 60 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

ethypharm - morphine sulfate - tablet prolonged release - 120 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

ethypharm - morphine sulfate - tablet prolonged release - 200 milligram

Izraēla - angļu - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - docetaxel - solution for infusion - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. docetaxel in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. non-small cell lung cancer: docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer: docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. prostate cancer: docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.esophageal cancer: docetaxel for the treatment of esophageal cancer. gastric cancer: docetaxel for the treatment of advanced gastric cancer. head and neck (scchn): docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Īrija - angļu - HPRA (Health Products Regulatory Authority)

rowex ltd - oxycodone hydrochloride - tablet prolonged release - 60 milligram - natural opium alkaloids

Īrija - angļu - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Īrija - angļu - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Īrija - angļu - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - docetaxel - concentrate for soln for inf - 10 mg/ml

Īrija - angļu - HPRA (Health Products Regulatory Authority)

hospira uk limited - docetaxel - concentrate for soln for inf - 10 micromol - docetaxel